UNSPSC 51283220: Oleandomycin phosphate

This classification denotes a macrolide antibiotic with the molecular formula C35H61NO12.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8681H0C27P, chemically known as oleandomycin, phosphate (1:1) (salt) but more generally known as oleandomycin phosphate, which bears US NIH Compound Identifier 72492. European Medicines Agency schedules Oleandomycin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03497MIG.

UNSPSC 51283220 Oleandomycin phosphate is a Commodity code that nominally identifies a specific macrolide antibiotic, but recent state and local procurement activity tagged under this code shows little alignment with pharmaceutical manufacturing or bulk antibiotic supply. Instead, the opportunities solicited reveal a broader pattern of health and emergency-response procurement spanning naloxone, first-aid medical supplies, generic pharmaceuticals, and direct-to-manufacturer prescription programs. The issuing bodies include county health departments, city fire services, state health agencies, and multi-state cooperative purchasing alliances. The mismatch between the code's nominal scope and actual buy suggests either misclassification in source data or that the code is being used as a catch-all placeholder for diverse pharmaceutical and health-supply procurements rather than as a targeted identifier for oleandomycin specifically.

Recent activity spans Florida, Texas, Minnesota, and participating cooperative-purchasing jurisdictions. Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives through competitive sealed bidding. The City of Tampa (ITB 26P00145, due March 13, 2026) sought 169 line items of medical and first-aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside with 5 percent bid discount. The Texas Health and Human Services Commission (RFI HHS0017013, April 3, 2026) issued a market-intelligence RFI on direct-to-manufacturer prescription programs for self-insured plans. The Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) sought manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities, with pricing evaluation weighted 75 percent on competitiveness and 10 percent on fixed-term pricing, effective July 1, 2026. The code shows substantive procurement activity but little relevant to oleandomycin specifically.